Skip to main content

DTwP-HepB-Hib Pentavalent MAP

Award type :
Product Development Award
Product type :
Vaccines
Award year :
2020
Project start date :
07 / 02 / 2020
Project end date :
10 / 30 / 2022
Project duration (months) :
27
Development stage :
Preclinical
Target disease :
DTwP-HepB-Hib (Pentavalent vaccine)
Region served :
Low- and Middle-Income Countries
Recipient organization / Country of funding recipient organization :
QuadMedicine / Republic of Korea
Collaborator(s) / Country :
University-Industry Foundation, Yonsei University Health System / Republic of Korea, LG Chem / Republic of Korea
Funding amount(KRW) :
1,270,000,000

This project aims to develop a compartmental microneedle array patch (MAP) containing pentavalent vaccine (DTwP-HepB-Hib), and assess the immunogenicity and efficacy compared to intramuscular (IM) administration in animal models. The project has already demonstrated the successful production of a pentavalent MAP which is stable for up to 12 months at room temperature and has high delivery efficiency. Pentavalent vaccine delivered through MAP elicited comparable antibody responses to IM injection. MAP delivery of pentavalent vaccine addresses a crisis in vaccine access and equity spurred by constraints in maintaining cold chain infrastructure in remote, high-burden areas and strengthens the use case of this platform for other vaccine targets.